A bipartisan coalition of House lawmakers has introduced The Medical Cannabis Research Act of 2019 (HR 601), to facilitate federally-approved clinical trials involving cannabis. The act ends the University of Mississippi’s existing monopoly on the growth of cannabis for clinical research purposes, by requiring the licensing of additional manufacturers. It is high time that lawmakers recognize this problem and take action to amend it so that investigators may conduct the same sort of high-quality clinical research with cannabis that they do with other substances.” At the time the bill passed committee, NORML Deputy Director Paul Armentano praised the effort, saying, “The federal hurdles in place that currently discourage clinicians from engaging in clinical cannabis research have long been onerous and irrational. To date, the US National Institute on Drug Abuse designates the University of Mississippi to be the sole provider of marijuana for FDA-approved research.
A bipartisan coalition of House lawmakers has introduced The Medical Cannabis Research Act of 2019 (HR 601), to facilitate federally-approved clinical trials involving cannabis.
Click here to send a message to your Representative and urge them to support the measure.
The act ends the University of Mississippi’s existing monopoly on the growth of cannabis for clinical research purposes, by requiring the licensing of additional manufacturers.
To date, the US National Institute on Drug Abuse designates the University of Mississippi to be the sole provider of marijuana for FDA-approved research. However, many of those...
Read the full article @ Norml